<?xml version="1.0" encoding="UTF-8"?>
<p>Arbidol (ARB) was licensed for the treatment of influenza and other respiratory viral infections in Russia and China [
 <xref rid="B72" ref-type="bibr">72</xref>,
 <xref rid="B73" ref-type="bibr">73</xref>]. Blaising and coauthors consider ARB to be a broad spectrum antiviral drug [
 <xref rid="B72" ref-type="bibr">72</xref>]. In addition, ARB has been reported to inhibit SARS-CoV 
 <italic>in vitro</italic>. Therefore, a clinical trial of ARB-treated COVID-19-positive patients has been registered [
 <xref rid="B65" ref-type="bibr">65</xref>].
</p>
